Pulse Biosciences Seeks Shareholder Nod for 2M Share Equity Plan Boost

TL;DR

**PLSE is asking shareholders to greenlight significant equity dilution to fuel executive and consultant compensation; vote 'FOR' if you believe in management's long-term vision, 'AGAINST' if you prioritize current shareholder value.**

AI Summary

Pulse Biosciences, Inc. (PLSE) is holding a Special Meeting of Stockholders on September 30, 2025, to vote on two key proposals. The first proposal seeks approval to amend the 2017 Equity Incentive Plan, increasing the number of shares issuable under the plan by 2,000,000 shares and modifying the definition of 'Consultant' to include employees engaged through an employer of record. The second proposal, contingent on the first's approval, is to ratify options awarded on August 9, 2024, and January 21, 2025, totaling up to 1,100,000 shares of common stock to an executive, directors, and consultants. The Board of Directors unanimously recommends a 'FOR' vote on both proposals, emphasizing the importance of equity incentives for attracting and retaining talent. The record date for voting is August 25, 2025, with 67,295,847 shares of common stock outstanding and entitled to vote. A quorum requires 33,647,924 shares to be present.

Why It Matters

This DEF 14A filing is crucial for investors as it directly impacts potential share dilution and executive compensation at Pulse Biosciences. Approving an additional 2,000,000 shares for the equity plan, alongside ratifying 1,100,000 previously awarded options, could dilute existing shareholder value. For employees and consultants, it signals the company's commitment to using equity as a retention and incentive tool, potentially boosting morale and alignment with long-term goals. In a competitive biotech landscape, robust equity plans are vital for attracting top talent, but investors must weigh this against the dilution impact on their holdings.

Risk Assessment

Risk Level: medium — The primary risk stems from potential share dilution. Proposal 1 seeks to increase the shares available under the Equity Plan by 2,000,000, and Proposal 2 ratifies options for up to 1,100,000 shares. With 67,295,847 shares outstanding as of August 25, 2025, these additions represent a potential dilution of approximately 4.6% (3,100,000 / 67,295,847), which could impact earnings per share and stock price.

Analyst Insight

Investors should carefully evaluate the potential dilution from the proposed 2,000,000 share increase and the ratification of 1,100,000 options against the perceived benefits of incentivizing management and consultants. Consider voting 'FOR' if you believe the long-term growth potential outweighs the short-term dilution, or 'AGAINST' if you are concerned about the impact on your existing stake.

Key Numbers

• 2,000,000 shares — Increase in shares for Equity Plan (Proposed increase in common stock issuable under the 2017 Equity Incentive Plan)
• 1,100,000 shares — Options awarded (Shares underlying options awarded on August 9, 2024, and January 21, 2025, subject to ratification)
• September 30, 2025 — Special Meeting Date (Date of the virtual Special Meeting of Stockholders)
• August 25, 2025 — Record Date (Date for determining stockholders entitled to vote at the Special Meeting)
• 67,295,847 shares — Common Stock Outstanding (Total shares of common stock outstanding and entitled to vote as of the record date)
• 33,647,924 shares — Quorum Requirement (Minimum number of shares required to be present for the Special Meeting to be properly held)

Key Players & Entities

• PULSE BIOSCIENCES, INC. (company) — Registrant for DEF 14A filing
• Paul A. LaViolette (person) — President, Chief Executive Officer and Co-Chairman of the Board of Directors
• Jon Skinner (person) — Designated proxy for the Special Meeting
• Broadridge Corporate Issuer Solutions, Inc. (company) — Transfer agent and vote tabulator
• SEC (regulator) — Securities and Exchange Commission
• The Nasdaq Stock Market (regulator) — Governing body for broker voting rules
• Delaware General Corporation Law (regulator) — Governing law for corporate actions

FAQ

Industry Context

Pulse Biosciences operates in the biotechnology sector, focusing on developing and commercializing its proprietary pulsed electric field (PEF) technology for therapeutic applications. This field is highly competitive, with numerous companies vying for innovation and market share in areas like oncology and dermatology. Success often hinges on clinical trial outcomes, regulatory approvals, and effective capital management to fund extensive research and development.

Regulatory Implications

The company's operations are subject to stringent regulatory oversight by bodies like the FDA. Any expansion of its equity incentive plans, particularly concerning eligibility and share issuance, must comply with securities laws and exchange listing requirements. The ratification of previously awarded options also falls under these regulatory frameworks.

What Investors Should Do

1. Review Proposal 1: Amendment to the 2017 Equity Incentive Plan
2. Review Proposal 2: Ratification of Options Awarded
3. Vote by the Record Date of August 25, 2025
4. Monitor Future Dilution

Key Dates

• 2025-09-30: Special Meeting of Stockholders — Stockholders will vote on proposals to amend the 2017 Equity Incentive Plan and ratify previously awarded options.
• 2025-08-25: Record Date — Determines which stockholders are entitled to vote at the Special Meeting.
• 2025-09-02: Proxy Statement Availability — First date stockholders can access the proxy materials for the Special Meeting.
• 2024-08-09: Option Award Date — One of the dates for options being presented for ratification at the Special Meeting.
• 2025-01-21: Option Award Date — One of the dates for options being presented for ratification at the Special Meeting.

Glossary

DEF 14A

A filing required by the SEC for companies holding an annual or special meeting of security holders, containing detailed information about the meeting and the matters to be voted upon. (This document provides the basis for the analysis of the upcoming stockholder meeting and the proposals being considered.)

Equity Incentive Plan

A plan established by a company to grant equity-based compensation, such as stock options or restricted stock, to employees, directors, and consultants. (The company is seeking to amend its 2017 Equity Incentive Plan to increase the number of shares available and broaden eligibility.)

Proxy

A legal designation by a stockholder authorizing another person to vote their shares on their behalf. (Stockholders are being asked to grant a proxy to vote on the proposed matters at the Special Meeting.)

Employer of Record (EOR)

A third-party organization that legally employs workers on behalf of another company, handling payroll, benefits, and compliance. (The proposed amendment to the Equity Plan includes changing the definition of 'Consultant' to allow awards to employees engaged through an EOR.)

Ratify

To confirm or approve an action that has already been taken. (Stockholders are being asked to ratify options that have already been awarded to executives, directors, and consultants.)

Year-Over-Year Comparison

This filing pertains to a special meeting and focuses on equity incentive plan amendments and option ratifications, rather than a comprehensive annual review. Therefore, direct year-over-year comparisons of financial metrics like revenue growth or margin changes are not applicable based on the provided text. The key focus is on the proposed changes to equity compensation and their potential impact on future share structure and employee incentives.

Key Financial Figures

• $0.001 — f shares of the Company's common stock, $0.001 par value per share (our "Common Stock"
• $16.49 — Q Global Market on August 25, 2025, was $16.49 per share. Description of the Plan Ame

Filing Documents

• plse20250901_def14a.htm (DEF 14A) — 226KB
• a01.jpg (GRAPHIC) — 145KB
• a02.jpg (GRAPHIC) — 134KB
• 0001437749-25-028189.txt ( ) — 1178KB
• plse-20241231.xsd (EX-101.SCH) — 4KB
• plse-20241231_def.xml (EX-101.DEF) — 2KB
• plse-20241231_lab.xml (EX-101.LAB) — 2KB
• plse-20241231_pre.xml (EX-101.PRE) — 1KB
• plse20250901_def14a_htm.xml (XML) — 1KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 14 OTHER INFORMATION 16 Annex A A-1 PULSE BIOSCIENCES, INC. PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS To Be Held at 4:00 p.m., Eastern Time, on September 30, 2025 GENERAL INFORMATION We are providing you with this Proxy Statement and the enclosed form of proxy in connection with the solicitation by our Board of Directors for use at our special meeting of stockholders (the "Special Meeting"). The Special Meeting will be conducted virtually via live audio webcast by visiting www.virtualshareholdermeeting.com/PLSE2025SM on September 30, 2025 at 4:00 p.m., Eastern Time. This Proxy Statement contains important information regarding our Special Meeting, the proposals on which you are being asked to vote, information you may find useful in determining how to vote, and information about voting procedures. As used herein, "we," "us," "our," "Pulse," or the "Company" refers to Pulse Biosciences, Inc., a Delaware corporation. This Proxy Statement and the accompanying proxy card or voting instruction form will first be made available to our stockholders on or about September 2, 2025. The information provided in the "question and answer" format below is for your convenience only and is merely a summary of the information contained in this Proxy Statement. You should read this entire Proxy Statement carefully. Information contained on or that can be accessed through our website is not intended to be incorporated by reference into this Proxy Statement and references to our website address in this Proxy Statement are inactive textual references only. QUESTIONS AND ANSWERS What is a proxy? A proxy is your legal designation of another person to vote the stock you own. The person you designate is your "proxy," and you give the proxy authority to vote your shares by submitting the enclosed proxy card, or if available, voting by telephone or the Internet. We have designated Paul A. LaVi

View Full Filing

View this DEF 14A filing on SEC EDGAR